Immunotherapy in Upper Tract Urothelial Carcinoma - Trial NCT06113367
Access comprehensive clinical trial information for NCT06113367 through Pure Global AI's free database. This phase not specified trial is sponsored by Assistance Publique - Hôpitaux de Paris and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 350 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Assistance Publique - Hôpitaux de Paris
Timeline & Enrollment
N/A
Nov 01, 2023
Feb 28, 2024
Primary Outcome
Overall survival on anti-PD-(L)1 immunotherapy
Summary
Upper-tract urothelial carcinoma (UTUC) is a rare tumor. Standard treatment of localized
 disease is most often radical nephroureterectomy.
 
 In advanced/metastatic disease, treatments follow the standards for urothelial carcinoma
 including platinum-based chemotherapy and anti-PD(L)1 (Programmed death (ligand) 1)
 immunotherapy, with no regard as to the primary disease site (bladder or upper tract). Given
 the rarity of UTUC, efficacy data in the UTUC subgroup of advanced urothelial carcinoma is
 scarce.
 
 UTUC show distinct pahological and molecular features, including higher prevalence of
 microsatellite instability and of abnormalities in the FGFR (fibroblast growth factor
 receptors) gene family. These specific features may impact outcomes of immunotherapy in
 advanced/metastatic UTUC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06113367
Non-Device Trial